– Study Results Highlight Potential Utility of Targeting Mannose 6-Phosphate Pathway to Treat Gaucher Disease and Mucolipidosis II – ST. LOUIS, Mo., – Feb. 11, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today the presentation of promising preclinical data at the …
Continue readingM6P Therapeutics Supports Rare Disease Day 2021 and Joins Global Movement to Increase Awareness of Rare Diseases
ST. LOUIS, Mo., – Feb. 25, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced its support for Rare Disease Day 2021 and commitment to the rare disease community. Rare Disease Day is an annual awareness day dedicated to elevating the public …
Continue readingM6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Board
ST. LOUIS, Mo., – Feb. 3, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced its scientific advisory board (SAB) that will support the Company’s mission of translating its innovative bicistronic-S1S3 technology platform into best-in-class therapies that address unmet needs within the LSD community. …
Continue reading